- Home
- ICCC vs CRVO Comparison
ICCC vs CRVO Comparison
Compare ICCC & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- CRVO
- Stock Information
- Founded
- ICCC 1982
- CRVO 2001
- Country
- ICCC United States
- CRVO United States
- Employees
- ICCC N/A
- CRVO N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- ICCC Health Care
- CRVO Health Care
- Exchange
- ICCC Nasdaq
- CRVO Nasdaq
- Market Cap
- ICCC 57.4M
- CRVO 67.4M
- IPO Year
- ICCC 1987
- CRVO N/A
- Fundamental
- Price
- ICCC $6.61
- CRVO $8.90
- Analyst Decision
- ICCC
- CRVO Strong Buy
- Analyst Count
- ICCC 0
- CRVO 6
- Target Price
- ICCC N/A
- CRVO $19.17
- AVG Volume (30 Days)
- ICCC 17.1K
- CRVO 113.7K
- Earning Date
- ICCC 11-12-2025
- CRVO 11-11-2025
- Dividend Yield
- ICCC N/A
- CRVO N/A
- EPS Growth
- ICCC N/A
- CRVO N/A
- EPS
- ICCC 0.20
- CRVO N/A
- Revenue
- ICCC $28,274,756.00
- CRVO $7,776,968.00
- Revenue This Year
- ICCC N/A
- CRVO N/A
- Revenue Next Year
- ICCC N/A
- CRVO N/A
- P/E Ratio
- ICCC $32.15
- CRVO N/A
- Revenue Growth
- ICCC 21.75
- CRVO N/A
- 52 Week Low
- ICCC $3.38
- CRVO $1.80
- 52 Week High
- ICCC $7.60
- CRVO $16.94
- Technical
- Relative Strength Index (RSI)
- ICCC 58.43
- CRVO 53.71
- Support Level
- ICCC $6.30
- CRVO $7.90
- Resistance Level
- ICCC $6.99
- CRVO $8.93
- Average True Range (ATR)
- ICCC 0.30
- CRVO 0.43
- MACD
- ICCC 0.06
- CRVO 0.08
- Stochastic Oscillator
- ICCC 69.06
- CRVO 85.54
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.